基于代谢组学和16S rRNA测序探究罗布麻叶总黄酮抗高脂血症的作用

Investigating the Anti-Hyperlipidemia Effects of Total Flavonoids from Folium Apocyni Veneti Using Metabolomics and 16S rRNA Sequencing

  • 摘要:
    目的 探究罗布麻叶总黄酮(TFA)的抗高脂血症(HLP)作用,并阐明其对肠道菌群组成及代谢功能的调节作用。
    方法 通过高脂饲料喂养建立HLP大鼠模型。造模同时分别给予阳性药辛伐他汀和不同剂量的TFA进行干预。末次给药后禁食,麻醉状态下腹主动脉取血,测定各组大鼠血清中甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、一氧化氮(NO)、超氧化物歧化酶(SOD)和丙二醛(MDA)水平;采用ELISA法测定血清血管紧张素Ⅱ(Ang-Ⅱ)、血管细胞黏附分子-1(VCAM-1)水平。采用非靶向代谢组学技术分析血清代谢物的差异,并使用16S rRNA测序检测肠道菌群结构的变化。将TFA降血脂的药理药效指标、肠道差异菌属与TFA所调控的差异代谢物进行相关性分析,进一步挖掘TFA所调控的代谢通路与其发挥药效和调控肠道菌群作用之间的关联。
    结果 TFA能有效降低模型大鼠肝脏和血清中的TG、TC和LDL-C,升高HDL-C,且能显著降低血清LDL-C/HDL-C与动脉硬化指数(AI)。此外,TFA能显著升高血清NO和SOD含量,降低Ang-Ⅱ、VCAM-1和MDA水平。代谢组学分析表明,TFA能改善模型大鼠的血清代谢紊乱,主要调控甘油磷脂代谢、泛酸和辅酶A(CoA)生物合成等通路。肠道菌群分析结果表明,TFA可降低厚壁菌门/拟杆菌门(F/B)的比值,同时抑制变形菌门与放线菌门的异常增殖。
    结论 TFA可以改善HLP大鼠脂质代谢、增强机体抗氧化能力、抑制自由基引起的脂质过氧化、对血管内皮具有一定保护作用,其作用机制可能与调控机体代谢及肠道菌群平衡相关。

     

    Abstract:
    OBJECTIVE To investigate the anti-hyperlipidemia effect of total flavonoids (TFA) from Folium Apocyni Veneti and to elucidate its regulatory role on gut microbiota composition and metabolic function.
    METHODS An hyperlipidemia rat model was established by feeding the rats with a high-fat diet. Simvastatin (a positive control drug) and three doses of TFA were administered concurrently with model establishment. After the last administration, the rats were fasted and blood was collected from the abdominal aorta under anesthesia. Serum levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), nitric oxide (NO), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured in each group. Serum levels of angiotensin Ⅱ (Ang-Ⅱ) and vascular cell adhesion molecule-1 (VCAM-1) were measured by ELISA. Serum metabolite differences were analyzed using non-targeted metabolomics techniques, and changes in gut microbiota structure were detected by 16S rRNA sequencing. Correlation analysis was conducted between the pharmacological and pharmacodynamic indicators and the differentially expressed gut microbiota of TFA in lowering blood lipids and the differentially regulated metabolites by TFA to further explore the relationship between the metabolic pathways regulated by TFA and its pharmacodynamic effects and its role in regulating gut microbiota.
    RESULTS TFA effectively reduced TG, TC, and LDL-C in the liver and serum, increased HDL-C, and significantly reduced serum LDL-C/HDL-C and the arteriosclerosis index (AI). Furthermore, TFA significantly increased serum NO and SOD levels and decreased Ang-II, VCAM-1, and MDA levels. Metabolomics analysis indicated that TFA improved serum metabolic disorders in model rats, mainly regulating pathways such as glycerophospholipid metabolism, pantothenic acid, and coenzyme A (CoA) biosynthesis. Gut microbiota analysis showed that TFA decreased the Firmicutes/Bacteroidetes (F/B) ratio and inhibited the abnormal proliferation of Proteobacteria and Actinobacteria.
    CONCLUSION TFA can improve lipid metabolism disorders, enhance antioxidant capacity, inhibit free radical-induced lipid peroxidation, and has a certain protective effect on vascular endothelium in HLP rats. Its mechanism may be related to the regulation of metabolism and gut microbiota balance.

     

/

返回文章
返回